Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy
Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy
复制标题
DOI：
10.1182/blood.v98.12.3473
复制
发表时间：
2001-12-01
期刊：
影响因子：
20.3
通讯作者：
Parravicini, C
中科院分区：
文献类型：
--
作者：
Corbellino, M;Bestetti, G;Parravicini, C
卡波西肉瘤相关疱疹病毒（KSHV）相关的多中心Castleman病（MCD）是潜在致命的。越来越多的证据表明，在EB病毒驱动的淋巴组织增生性疾病移植后，KSHV DNA负荷在外周血单核细胞（PBMC）可能是最准确的疾病活动的标志物。本报告描述了一名人类免疫缺陷病毒患者，在诊断为KSHV相关MCD后，通过临床和定量聚合酶链反应对PBMCs中的KSHV DNA序列进行了3年以上的随访。治疗与抗疱疹病毒剂西多福韦，抗人白细胞介素-6抗体BE-8，抗胚细胞化疗，并结合抗逆转录病毒药物没有实现持久的临床或病毒学缓解的疾病。相比之下，抗CD 20单克隆抗体利妥昔单抗的给药耐受性良好，临床症状和KSHV病毒血症缓解14个月。利妥昔单抗应添加到KSHV相关MCD的治疗设备中。（血。2001;98：3473-3475）（C）2001由美国血液学学会。
Kaposi sarcoma-associated herpesvirus (KSHV)-related multicentric Castleman disease (MCD) is potentially lethal. Growing evidence Indicates that, as in Epstein-Barr virus-driven lymphoproliferative disorders after transplantation, KSHV DNA burden in peripheral blood mononuclear cells (PBMCs) may represent the most accurate marker of disease activity. This report describes a patient with human immunodeficiency virus who was followed up clinically and by quantitative polymerase chain reaction for KSHV DNA sequences in PBMCs for more than 3 years following the diagnosis of KSHV-related MCD. Therapy with the antiherpesvirus agent cidofovir, antihuman interleukin-6 antibody BE-8, antiblastic chemotherapy, and combination antiretroviral agents did not achieve durable clinical or virologic remission of the disease. By contrast, administration of the anti-CD20 monoclonal antibody rituximab was well tolerated and allowed a 14-month remission of clinical symptoms and KSHV viremia. Rituximab should be added to the therapeutic armamentarium for KSHV-related MCD. (Blood. 2001;98:3473-3475) (C) 2001 by The American Society of Hematology.